Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Toronto Stock Exchange  >  Bausch Health Companies Inc       CA91911K1021

BAUSCH HEALTH COMPANIES INC
My previous session
Most popular
  Report  
 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE
Quotes 5-day view   End-of-day quote. End-of-day quote Toronto Stock Exchange
07/09/2018 07/10/2018 07/11/2018 07/12/2018 07/13/2018 Date
30.88 31.18 31.36 31.86 30.8 Last
1078107 1018037 1331258 848750 1232408 Volume
+2.73% +0.97% +0.58% +1.59% -3.33% Change
Financials (USD)
Sales 2018 8 472 M
EBIT 2018 3 104 M
Net income 2018 -3 712 M
Debt 2018 23 890 M
Yield 2018 -
Sales 2019 8 441 M
EBIT 2019 3 092 M
Net income 2019 -1 246 M
Debt 2019 22 701 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 3,85x
EV / Sales2019 3,72x
Capitalization 8 721 M
More Financials
Company
Bausch Health Cos., Inc. engages in the development, manufacture, and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products.It operates through the following segments: The Bausch + Lomb/International, Branded Rx, and U.S.... 
Sector
Pharmaceuticals
Calendar
10/02Presentation
More about the company
Surperformance© ratings of Bausch Health Companies In
Trading Rating : Investor Rating :
More Ratings
Latest news on BAUSCH HEALTH COMPANIES IN
09/18TUESDAY 9/18 INSIDER BUYING REPORT : Bhc, ibtx
AQ
09/18TODAY'S RESEARCH REPORTS ON TRENDING : Bausch Health Companies and OPKO Health
AC
09/14BAUSCH HEALTH : Announces Resolution of XIFAXAN Intellectual Property Litigation
AQ
09/14GLAXOSMITHKLINE : Xenon further strengthens balance sheet with $63M follow-on
AQ
09/13BAUSCH HEALTH : + Lomb Announces Publication Of Pivotal Phase 3 Data On Lotepred..
AQ
09/13TODAY’S RESEARCH REPORTS ON STOCKS T : Bausch Health Companies and Vital Therapi..
AC
09/13BAUSCH HEALTH : Salix Announces U.S. Launch of PLENVU, the First and Only 1-Lite..
AQ
09/13BAUSCH HEALTH : Reduces Debt by Additional $107 Million, Eliminating All Remaini..
AQ
09/13BAUSCH HEALTH : Norgine and its partner salix announce the us launch of plenvu
AQ
09/12BAUSCH HEALTH : Up Over 12%, on Pace for Largest Percent Increase Since Nov 2017..
DJ
More news
Sector news : Pharmaceuticals - NEC
03:05aAs China builds biotech sector, cash floods U.S. startups
RE
09/23ASTRAZENECA CEO WARNS OF MEDICINE SH : Sunday Times
RE
09/22J&J UNIT : Esketamine Study Didn't Show Statistical Significance for Primary End..
DJ
09/21JOHNSON & JOHNSON : J&J Unit Agrees To Sell Sterilization Unit for $2.7 Billion
DJ
09/21EMA Nod to Eli Lilly Drug Stokes Competition in Migraine Prevention Market
DJ
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
07/16Valeant becomes Bausch Health Companies today 
07/13Bausch Health Companies Inc. completes name change 
07/13Summer Screens And Shorts Coming Out 
07/12Drug prices still marching upward - Bloomberg 
07/11LUCEMYRA : An Underappreciated Opportunity For Valeant 
Chart BAUSCH HEALTH COMPANIES INC
Duration : Period :
Bausch Health Companies Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
 
Mean consensus HOLD
Number of Analysts 16
Average target price 17,2 $
Spread / Average Target -31%
EPS Revisions
Managers
NameTitle
Joseph C. Papa Chairman & Chief Executive Officer
Paul S. Herendeen Chief Financial Officer & Executive Vice President
Jerzy Janeczko Head-Information Technology
Tage Ramakrishna Chief Medical Officer, President-R&D
Robert N. Power Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
BAUSCH HEALTH COMPANIES INC13.97%8 751
JOHNSON & JOHNSON2.26%383 312
PFIZER21.65%258 285
NOVARTIS-0.63%216 108
ROCHE HOLDING LTD.-4.60%211 501
MERCK AND COMPANY26.36%189 092